Effect of food on the pharmacokinetics of the WEE1 inhibitor adavosertib (AZD1775) in patients with advanced solid tumors

被引：0
作者：
Mats Någård
Mei-Lin Ah-See
Karen So
Marit Vermunt
Fiona Thistlethwaite
Mariette Labots
Patricia Roxburgh
Alain Ravaud
Mario Campone
Liselot Valkenburg-van Iersel
Lone Ottesen
Yan Li
Ganesh Mugundu
机构：
[1] R&D Clinical Pharmacology and Safety Sciences,Clinical Pharmacology and Quantitative Pharmacology
[2] AstraZeneca,Late Stage Development, Oncology R&D
[3] AstraZeneca,Clinical Pharmacology Biologics and Bioanalysis, Clinical Pharmacology and Safety Science, BioPharmaceuticals R&D
[4] The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital,Clinical Pharmacology and Quantitative Pharmacology, R&D Clinical Pharmacology and Safety Sciences
[5] The Christie NHS Foundation Trust and University of Manchester,undefined
[6] Cancer Center Amsterdam,undefined
[7] Amsterdam UMC,undefined
[8] Beaston West of Scotland Cancer Centre and University of Glasgow,undefined
[9] Bordeaux University Hospital,undefined
[10] ICO – Site René,undefined
[11] Maastricht University Medical Centre,undefined
[12] AstraZeneca,undefined
[13] AstraZeneca,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2020年 / 86卷
关键词：
Adavosertib; Food effect; Pharmacokinetics; Oncology; WEE1;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：97 / 108
页数：11
相关论文
共 50 条
  • [41] A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors
    Suzanne Leijen
    Patricia M. M. B. Soetekouw
    T. R. Jeffry Evans
    Marianne Nicolson
    Jan H. M. Schellens
    Maria Learoyd
    Lynda Grinsted
    Victoria Zazulina
    Thinn Pwint
    Mark Middleton
    Cancer Chemotherapy and Pharmacology, 2011, 68 : 1619 - 1628
  • [42] Population Pharmacokinetics of TAK-931, a Cell Division Cycle 7 Kinase Inhibitor, in Patients With Advanced Solid Tumors
    Zhou, Xiaofei
    Ouerdani, Aziz
    Diderichsen, Paul Matthias
    Gupta, Neeraj
    JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 62 (03) : 422 - 433
  • [43] A Phase I Study of the Pharmacokinetics and Safety of Ipatasertib, an Akt Inhibitor in Chinese Patients With Locally Advanced or Metastatic Solid Tumors
    Zhang, Jian
    Liu, Rujiao
    Sutaria, Dhruvit
    Sane, Rucha
    Fan, Minhao
    Wang, Rui
    Song, Grace
    Chen, Kui
    Arzumanova, Ksenia
    Hu, Xichun
    CLINICAL THERAPEUTICS, 2025, 47 (02) : 128 - 134
  • [44] Olaparib tablet formulation: effect of food on the pharmacokinetics after oral dosing in patients with advanced solid tumours
    Ruth Plummer
    Helen Swaisland
    Karin Leunen
    Carla M. L. van Herpen
    Guy Jerusalem
    Jacques De Grève
    Martijn P. Lolkema
    Patricia Soetekouw
    Morten Mau-Sørensen
    Dorte Nielsen
    James Spicer
    Anitra Fielding
    Karen So
    Wendy Bannister
    L. Rhoda Molife
    Cancer Chemotherapy and Pharmacology, 2015, 76 : 723 - 729
  • [45] Olaparib tablet formulation: effect of food on the pharmacokinetics after oral dosing in patients with advanced solid tumours
    Plummer, Ruth
    Swaisland, Helen
    Leunen, Karin
    van Herpen, Carla M. L.
    Jerusalem, Guy
    De Greve, Jacques
    Lolkema, Martijn P.
    Soetekouw, Patricia
    Mau-Sorensen, Morten
    Nielsen, Dorte
    Spicer, James
    Fielding, Anitra
    So, Karen
    Bannister, Wendy
    Molife, L. Rhoda
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 76 (04) : 723 - 729
  • [46] Effect of coadministration of ketoconazole, a strong CYP3A4 inhibitor, on pharmacokinetics and tolerability of motesanib diphosphate (AMG 706) in patients with advanced solid tumors
    Patricia LoRusso
    Elisabeth I. Heath
    Jesse McGreivy
    Yu-Nien Sun
    Rebeca Melara
    Lucy Yan
    Lisa Malburg
    Megan Ingram
    Jeffrey Wiezorek
    Li Chen
    Mary Jo Pilat
    Investigational New Drugs, 2008, 26
  • [47] Effect of coadministration of ketoconazole, a strong CYP3A4 inhibitor, on pharmacokinetics and tolerability of motesanib diphosphate (AMG 706) in patients with advanced solid tumors
    LoRusso, Patricia
    Heath, Elisabeth I.
    McGreivy, Jesse
    Sun, Yu-Nien
    Melara, Rebeca
    Yan, Lucy
    Malburg, Lisa
    Ingram, Megan
    Wiezorek, Jeffrey
    Chen, Li
    Pilat, Mary Jo
    INVESTIGATIONAL NEW DRUGS, 2008, 26 (05) : 455 - 462
  • [48] Safety, tolerability and pharmacokinetics of the fibroblast growth factor receptor inhibitor AZD4547 in Japanese patients with advanced solid tumours: a Phase I study
    Hideo Saka
    Chiyoe Kitagawa
    Yoshihito Kogure
    Yasuo Takahashi
    Koshi Fujikawa
    Tamotsu Sagawa
    Satoru Iwasa
    Naoki Takahashi
    Taro Fukao
    Catherine Tchinou
    Dónal Landers
    Yasuhide Yamada
    Investigational New Drugs, 2017, 35 : 451 - 462
  • [49] Safety, tolerability and pharmacokinetics of the fibroblast growth factor receptor inhibitor AZD4547 in Japanese patients with advanced solid tumours: a Phase I study
    Saka, Hideo
    Kitagawa, Chiyoe
    Kogure, Yoshihito
    Takahashi, Yasuo
    Fujikawa, Koshi
    Sagawa, Tamotsu
    Iwasa, Satoru
    Takahashi, Naoki
    Fukao, Taro
    Tchinou, Catherine
    Landers, Donal
    Yamada, Yasuhide
    INVESTIGATIONAL NEW DRUGS, 2017, 35 (04) : 451 - 462
  • [50] Phase I study to assess the pharmacokinetics and the effect on cardiac repolarization of amrubicin and amrubicinol in patients with advanced solid tumors
    Nianhang Chen
    Sant P. Chawla
    Elena Gabriela Chiorean
    William L. Read
    Mayer Gorbaty
    Alain C. Mita
    Lotus Yung
    Peter Bryan
    Richard McNally
    Markus F. Renschler
    Sunil Sharma
    Cancer Chemotherapy and Pharmacology, 2013, 71 : 1083 - 1094
12345